Comerica Securities Inc. reduced its holdings in shares of Gilead Sciences (NASDAQ:GILD) by 4.4% in the 1st quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 35,418 shares of the biopharmaceutical company’s stock after selling 1,643 shares during the quarter. Comerica Securities Inc.’s holdings in Gilead Sciences were worth $2,670,000 at the end of the most recent quarter.
A number of other institutional investors and hedge funds have also added to or reduced their stakes in GILD. Capital International Investors grew its stake in Gilead Sciences by 86.6% during the third quarter. Capital International Investors now owns 11,217,015 shares of the biopharmaceutical company’s stock worth $908,803,000 after buying an additional 5,205,983 shares during the period. Sanders Capital LLC lifted its position in shares of Gilead Sciences by 102.9% during the fourth quarter. Sanders Capital LLC now owns 9,910,493 shares of the biopharmaceutical company’s stock worth $757,119,000 after purchasing an additional 5,026,015 shares in the last quarter. Skandinaviska Enskilda Banken AB publ lifted its position in shares of Gilead Sciences by 230.0% during the third quarter. Skandinaviska Enskilda Banken AB publ now owns 4,927,585 shares of the biopharmaceutical company’s stock worth $399,233,000 after purchasing an additional 3,434,450 shares in the last quarter. CI Global Investments Inc. lifted its position in shares of Gilead Sciences by 5,461.1% during the fourth quarter. CI Global Investments Inc. now owns 3,317,627 shares of the biopharmaceutical company’s stock worth $237,675,000 after purchasing an additional 3,257,969 shares in the last quarter. Finally, Amundi Pioneer Asset Management Inc. lifted its position in shares of Gilead Sciences by 53.3% during the fourth quarter. Amundi Pioneer Asset Management Inc. now owns 9,054,685 shares of the biopharmaceutical company’s stock worth $648,679,000 after purchasing an additional 3,148,128 shares in the last quarter. Institutional investors own 78.16% of the company’s stock.
A number of research firms have recently commented on GILD. Barclays reduced their target price on shares of Gilead Sciences from $95.00 to $90.00 and set a “buy” rating on the stock in a research report on Wednesday, May 2nd. Leerink Swann set a $72.00 target price on shares of Gilead Sciences and gave the stock a “market perform” rating in a research report on Wednesday, May 2nd. BidaskClub cut shares of Gilead Sciences from a “sell” rating to a “strong sell” rating in a research report on Friday, May 4th. Needham & Company LLC reissued a “hold” rating on shares of Gilead Sciences in a research report on Wednesday, May 2nd. Finally, Zacks Investment Research cut shares of Gilead Sciences from a “buy” rating to a “hold” rating in a research report on Monday, May 7th. One equities research analyst has rated the stock with a sell rating, ten have assigned a hold rating, fifteen have issued a buy rating and one has assigned a strong buy rating to the company. Gilead Sciences presently has an average rating of “Buy” and a consensus target price of $88.14.
In other Gilead Sciences news, Chairman John C. Martin sold 50,000 shares of the stock in a transaction on Thursday, March 1st. The shares were sold at an average price of $78.65, for a total transaction of $3,932,500.00. Following the sale, the chairman now directly owns 3,067,762 shares of the company’s stock, valued at $241,279,481.30. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, EVP Gregg H. Alton sold 14,435 shares of the stock in a transaction on Tuesday, February 20th. The stock was sold at an average price of $81.54, for a total transaction of $1,177,029.90. The disclosure for this sale can be found here. Insiders have sold 241,102 shares of company stock worth $18,237,884 over the last three months. 1.16% of the stock is owned by corporate insiders.
GILD opened at $67.55 on Thursday. The firm has a market capitalization of $87.18 billion, a P/E ratio of 7.89, a P/E/G ratio of -5.83 and a beta of 1.19. The company has a debt-to-equity ratio of 1.32, a quick ratio of 2.75 and a current ratio of 2.84. Gilead Sciences has a 12-month low of $67.01 and a 12-month high of $67.62.
Gilead Sciences (NASDAQ:GILD) last issued its earnings results on Tuesday, May 1st. The biopharmaceutical company reported $1.48 earnings per share for the quarter, missing the Zacks’ consensus estimate of $1.67 by ($0.19). The business had revenue of $5.09 billion for the quarter, compared to analyst estimates of $5.40 billion. Gilead Sciences had a return on equity of 45.49% and a net margin of 14.03%. The firm’s revenue for the quarter was down 21.8% on a year-over-year basis. During the same period last year, the company posted $2.23 earnings per share. equities research analysts anticipate that Gilead Sciences will post 5.75 EPS for the current fiscal year.
The firm also recently announced a quarterly dividend, which will be paid on Thursday, June 28th. Shareholders of record on Friday, June 15th will be issued a dividend of $0.57 per share. The ex-dividend date of this dividend is Thursday, June 14th. This represents a $2.28 dividend on an annualized basis and a dividend yield of 3.38%. Gilead Sciences’s dividend payout ratio (DPR) is 26.64%.
Gilead Sciences Profile
Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes therapeutics in the areas of unmet medical needs in the United States, Europe, and internationally. The company's products include Biktarvy, Descovy, Odefsey, Genvoya, Stribild, Complera/Eviplera, Atripla, Truvada, Viread, Emtriva, and Tybost for the treatment of human immunodeficiency virus (HIV) infection in adults; and Vosevi, Vemlidy, Epclusa, Harvoni, Sovaldi, Viread, and Hepsera products for treating liver diseases.
Receive News & Ratings for Gilead Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences and related companies with MarketBeat.com's FREE daily email newsletter.